Keyphrases
25Mg
11%
Acute Changes
23%
Airway
46%
Bacterial Load
46%
Brensocatib
46%
Bronchiectasis
23%
Budesonide
31%
Clinical Status
18%
Community-acquired Pneumonia
23%
COVID-19
100%
COVID-19 Infection
11%
COVID-19 Pandemic
23%
Dipeptidyl Peptidase 1
46%
Fatal COVID-19
11%
Fluticasone Propionate
31%
Healthcare Workers
46%
Hospitalized Patients
49%
Inclusion Criteria
11%
Inhaled Corticosteroids
46%
Microbiome
46%
Nasopharyngeal Swab
15%
Neutrophil Elastase
16%
Neutrophilic Inflammation
23%
Neutrophils
23%
Oral Inhibitors
11%
Oxygen Saturation
11%
Patients with COVID-19
23%
Placebo
16%
Placebo Groups
13%
Placebo-controlled Trial
23%
Precision Medicine
23%
Protective Effect
23%
Proteome
23%
Pulmonary Involvement
11%
Randomized Controlled Trial
46%
Randomized Placebo-controlled Trial
46%
Reinfection
12%
Risk Factors
13%
Salmeterol
31%
SARS-CoV-2 Antibodies
23%
SARS-CoV-2 Infection
20%
Scottish
46%
Seroprevalence
25%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
25%
Severe Disease
20%
SFX-01
23%
Sputum
20%
Supplemental Oxygen
11%
Sustained Change
23%
UK Hospitals
11%
Medicine and Dentistry
Adverse Event
12%
Anti-Inflammatory Drug
5%
Antioxidant
5%
Biological Marker
7%
Blood Pressure
5%
Bronchiectasis
23%
Budesonide/Formoterol
46%
Chronic Obstructive Pulmonary Disease
46%
Community-Acquired Pneumonia
23%
COVID-19
69%
Dipeptidyl Peptidase
46%
Disease
10%
Fluticasone
46%
Formoterol
15%
Induced Sputum
7%
Infection
30%
Lymphocyte
7%
Microbiome
46%
Nasopharyngeal Swab
7%
Neutrophil
12%
Oxygen Saturation
7%
Personalized Medicine
23%
Physical Examination
7%
Placebo
69%
Randomized Controlled Trial
46%
Reinfection
11%
Salmeterol
46%
Serine Proteinase
14%
Serositis
5%
Severe Acute Respiratory Syndrome Coronavirus 2
36%
Sputum
31%
Sulforaphane
11%
Transcription Factor Nrf2
11%